medigraphic.com

2011, Number 2

<< Back Next >>

Rev Hematol Mex 2011; 12 (2)

Prasugrel resistance may be linked to the sticky platelet syndrome. Report of one case

Calderón-Cruz B, Pérez-González A, Peña-Duque MA, Vargas-Alarcón G, Fragoso-Lona JM, Martínez-Ríos MA, Herrera-González A, Valente-Acosta B, Quintanar-Trejo LE, Peña-Díaz A

Language: English
References: 20
Page: 105-109
PDF size: 90.12 Kb.


ABSTRACT

Background: Prasugrel is the most potent antiplatelet agent, even more than clopidogrel and is an alternative for the treatment and prevention of acute coronary syndromes. Despite the effectiveness of these drugs, it could be an inadequate response to reduce the hyperactivity of platelets measured by platelet aggregation test.
Patients and Methods: We studied six consecutive patients undergoing percutaneous coronary intervention which received a 60mg loading dose of prasugrel. Platelet aggregation was performed using as agonists ADP and epinephrine, were identified gene polymorphisms ABCB1, CYP2C19, CYP3A5 and P2RY12 and tissue factor was measured by ELISA.
Results: One of the six patients showed platelet hyperactivity even after treatment with prasugrel and clopidogrel, and 3.6 fold tissue factor in plasma compared with patients studied without platelet hyperactivity. No patient had the polymorphisms studied.
Conclusion: We report the case of a patient showing decreased response to prasugrel and clopidogrel manifesting with platelet hyperactivity.


REFERENCES

  1. Ben-Dor I, Kleiman NS, Lev E. Assessment, Mechanisms, and Clinical Implication of Variability in Platelet Response to Aspirin and Clopidogrel Therapy. Am J Cardiol 2009; 104: 227–233

  2. Testa L, Bhindi L, Van Gaal WJ, Latini RA, Pizzocri S, Lanotte S, Biondi Zoccai GGL, Valgimigli M, Laudisa ML, Brambilla N, Banning AP, Bedogni F. What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. Q J Med 2010; 103:367–377

  3. Wiviott SD, Trenk D, Frelinger AL, O’Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E, for the PRINCIPLE-TIMI 44 Investigators. Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention. Circulation 2007;116:2923-2932

  4. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. European Heart Journal 2006; 27:1166–1173

  5. Wallentin L, Varenhorst C, James S, Erlinge D, O¨ Braun O, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. European Heart Journal 2008; 29:21–30

  6. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E. Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38. Circulation 2009;119:2758-2764

  7. Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Stephen Wiviott, Antman E, Braunwald E, Cohen DJ. Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention. Circulation 2010;121:71-79.

  8. Frelinger AL 3rd, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007;98:192-200.

  9. Frelinger AL 3rd, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, Fox ML, Sugidachi A, Winters KJ, Furman MI, Michelson AD The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities J Thromb Haemost. 2008; 6:359-65.

  10. Bhatt DL. Prasugrel in clinical practice. N Engl J Med 2009;36:1-3

  11. Varenhorst C, James S, Erlinge D, Brandt JT, Braun O, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close SL. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamics responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. European Heart Journal 2009; 30:1744–1752

  12. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-1319

  13. Baker WL, White CM. Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes. Am J Cardiovasc Drugs 2009; 9: 213-229.

  14. Mammen EF. Sticky platelet syndrome. Semin Thromb Hemost. 1999; 25:361-365.

  15. Parra Ortega I, Estrada Gómez RA, Ruiz Argüelles GJ. Síndrome de las plaquetas pegajosas, la condición de trombofilia heredada más frecuente en pacientes mexicanos. Medicina Universitaria 2007;9:20-23

  16. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, López-Martínez B. El “Síndrome de las plaquetas pegajosas” una causa frecuente pero ignorada de trombofilia. Rev Invest Clin 2002; 54: 394-196.

  17. Cesarman-Maus G. Revista de Hematología

  18. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Research 1991;19:5444

  19. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-75.

  20. Silvano M, Zambon CF, De Rosa G, Plebani M, Pengo V, Napodano M, Padrini R. A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. Journal of thrombosis and thrombolysis 2011;31:233-234.




2020     |     www.medigraphic.com